Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...
The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 performance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback